PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11882318-3	2002	The goal of the present study was to determine the effect of the ACE inhibitor Ramipril on the progression of atherosclerosis in apolipoprotein-E-deficient (E0) mice with already advanced atherosclerosis.	Ramipril	79-87	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	65-68	
19578502-4	2008	RESULTS: ApoE-/- mice were treated with an ACE inhibitor ramipril and HMG-CoA reductase inhibitor simvastatin.	Ramipril	57-65	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	43-46	
15569856-4	2005	In lungs from mice treated with the ACE inhibitor ramipril for 5 days, COX-2 expression was increased.	Ramipril	50-58	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	36-39	
11882318-10	2002	We thus conclude that administration of the ACE inhibitor Ramipril to E0 mice, which already exhibit significant atherosclerosis, blocked the progression of the atherosclerotic lesion build-up, a phenomenon that could be related to Ramipril-induced inhibition of Ox-LDL uptake by macrophages.	Ramipril	58-66	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	44-47	
11882318-10	2002	We thus conclude that administration of the ACE inhibitor Ramipril to E0 mice, which already exhibit significant atherosclerosis, blocked the progression of the atherosclerotic lesion build-up, a phenomenon that could be related to Ramipril-induced inhibition of Ox-LDL uptake by macrophages.	Ramipril	232-240	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	44-47	
10630734-1	2000	We investigated the mechanism of the antiatherosclerotic effect of the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in the apolipoprotein (apo) E-deficient mice.	Ramipril	118-126	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	71-100	
10630734-1	2000	We investigated the mechanism of the antiatherosclerotic effect of the angiotensin-converting enzyme (ACE) inhibitor, ramipril, in the apolipoprotein (apo) E-deficient mice.	Ramipril	118-126	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	102-105	
10630734-6	2000	Ramipril (1 mg/kg/day) that was still adequate to reduce their plasma ACE activity and LDL propensity to lipid peroxidation was insufficient to reduce their blood pressure.	Ramipril	0-8	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	70-73	
33807982-2	2021	We aimed to elucidate the impact of early treatment with the ACE inhibitor ramipril on the hematopoietic response after MI, as well as on the chronic systemic and vascular inflammation.	Ramipril	75-83	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	61-64	
34349658-3	2021	We assessed the effect of the RAS modulator, ramipril, an angiotensin converting-enzyme inhibitor in a mouse model of OXP-induced acute pain syndrome.	Ramipril	45-53	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	58-87	
25441633-6	2015	In vivo interaction of the cardiovascular drugs metoprolol (beta-blocker) and ramipril (ACE inhibitor) with the anaphylactic response was determined.	Ramipril	78-86	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	88-91	
24487585-6	2014	Administration of the ACE inhibitor ramipril increased Abeta levels in AD+ACE(10/10) mice compared with the levels induced by the ACE-independent vasodilator hydralazine.	Ramipril	36-44	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	22-25	
24487585-6	2014	Administration of the ACE inhibitor ramipril increased Abeta levels in AD+ACE(10/10) mice compared with the levels induced by the ACE-independent vasodilator hydralazine.	Ramipril	36-44	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	74-77	
24487585-6	2014	Administration of the ACE inhibitor ramipril increased Abeta levels in AD+ACE(10/10) mice compared with the levels induced by the ACE-independent vasodilator hydralazine.	Ramipril	36-44	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	74-77	
34068941-3	2021	We explored the renoprotective effect of an inhibitor of K63-Ub (NSC697923), alone or in combination with the ACE-inhibitor ramipril, in vitro and in vivo.	Ramipril	124-132	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	110-113	
27590905-1	2016	Statins, such as simvastatin, and ACE inhibitors (ACEis), such as ramipril, are standard therapies for the prevention and treatment of cardiovascular diseases.	Ramipril	66-74	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	34-37	
24244677-5	2013	Subgroups of animals were treated with the Rac-1 inhibitor EHT1846, the ROCK inhibitor SAR407899 and the ACE inhibitor Ramipril.	Ramipril	119-127	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	105-108	
22374176-3	2012	Furthermore, we aimed to compare the efficacy of coenzyme Q(10) to that of the ACE inhibitor ramipril.	Ramipril	93-101	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	79-82